Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JAGX Jaguar Animal Health	$2.10 -5.4%	$2.82	$1.93 ▼ $35.25	$4.26M	0.43	99,053 shs	39,859 shs
PCSA Heatwurx	$0.23 +1.6%	$0.25	$0.15 ▼ $1.80	$2.70M	1.32	4.67 million shs	37.84 million shs
SONN Sonnet BioTherapeutics	$2.88 -3.4%	$3.14	$1.08 ▼ $19.30	$9.43M	1.04	3.44 million shs	400,796 shs
TRVN Trevena	$0.25	$0.94	$0.25 ▼ $7.85	$240K	0.41	2,047 shs	22 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JAGX Jaguar Animal Health	-5.41%	+2.94%	-19.54%	-75.32%	-92.15%
PCSA Heatwurx	+1.58%	+10.00%	+8.80%	-2.57%	-87.09%
SONN Sonnet BioTherapeutics	-3.36%	-13.25%	-35.57%	+125.00%	-51.36%
TRVN Trevena	0.00%	-72.53%	-72.53%	-79.34%	-95.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JAGX Jaguar Animal Health	1.8474 of 5 stars	3.5	3.0	1.1	0.0	0.6
PCSA Heatwurx	2.177 of 5 stars	3.5	2.0	0.4	1.7	1.3
SONN Sonnet BioTherapeutics	2.5074 of 5 stars	3.5	2.0	2.0	0.0	0.0
TRVN Trevena	1.5664 of 5 stars	3.0	3.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JAGX Jaguar Animal Health	3.00	Buy	$60.00	2,757.14% Upside
PCSA Heatwurx	3.00	Buy	$2.00	765.43% Upside
SONN Sonnet BioTherapeutics	3.00	Buy	$20.00	594.44% Upside
TRVN Trevena	2.00	Hold	$5.00	1,900.00% Upside

Current Analyst Ratings Breakdown

Latest TRVN, SONN, JAGX, and PCSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/30/2025	PCSA Heatwurx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $2.00
5/19/2025	JAGX Jaguar Animal Health	First Berlin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JAGX Jaguar Animal Health	$11.69M	0.34	N/A	N/A	$12.29 per share	0.17
PCSA Heatwurx	N/A	N/A	N/A	N/A	$0.46 per share	N/A
SONN Sonnet BioTherapeutics	$20K	456.48	N/A	N/A	($0.71) per share	-4.06
TRVN Trevena	$443K	0.54	N/A	N/A	($11.07) per share	-0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JAGX Jaguar Animal Health	-$38.49M	N/A	0.00	N/A	N/A	-343.92%	-432.91%	-71.25%	8/12/2025 (Estimated)
PCSA Heatwurx	-$11.85M	-$3.08	N/A	N/A	N/A	N/A	-319.56%	-232.40%	8/12/2025 (Estimated)
SONN Sonnet BioTherapeutics	-$7.44M	N/A	0.00	∞	N/A	N/A	-777.92%	-271.32%	8/13/2025 (Estimated)
TRVN Trevena	-$40.29M	-$47.04	N/A	N/A	N/A	N/A	N/A	-119.55%	N/A

Latest TRVN, SONN, JAGX, and PCSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q3 2025	SONN Sonnet BioTherapeutics	-$0.49	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	JAGX Jaguar Animal Health	-$7.13	N/A	N/A	N/A	$3.27 million	N/A
8/12/2025	Q2 2025	PCSA Heatwurx	-$0.23	-$0.25	-$0.02	-$0.25	N/A	N/A
5/15/2025	Q1 2025	JAGX Jaguar Animal Health	-$18.50	-$16.70	+$1.80	-$16.70	$3.29 million	$3.50 million
5/13/2025	Q2 2025	SONN Sonnet BioTherapeutics	-$0.92	-$0.89	+$0.03	-$0.89	N/A	N/A
5/8/2025	Q1 2025	PCSA Heatwurx	-$0.77	-$0.30	+$0.47	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JAGX Jaguar Animal Health	N/A	N/A	N/A	N/A	N/A
PCSA Heatwurx	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JAGX Jaguar Animal Health	22.20	1.08	0.70
PCSA Heatwurx	N/A	2.93	2.93
SONN Sonnet BioTherapeutics	N/A	1.03	1.03
TRVN Trevena	N/A	2.42	2.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JAGX Jaguar Animal Health	12.04%
PCSA Heatwurx	91.93%
SONN Sonnet BioTherapeutics	9.45%
TRVN Trevena	13.56%

Insider Ownership

Company	Insider Ownership
JAGX Jaguar Animal Health	4.55%
PCSA Heatwurx	9.60%
SONN Sonnet BioTherapeutics	2.00%
TRVN Trevena	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JAGX Jaguar Animal Health	50	1.91 million	1.83 million	No Data
PCSA Heatwurx	20	11.88 million	10.74 million	Not Optionable
SONN Sonnet BioTherapeutics	10	3.17 million	3.10 million	Not Optionable
TRVN Trevena	40	959,000	841,000	Optionable

TRVN, SONN, JAGX, and PCSA Headlines

Recent News About These Companies

Softball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honored

July 8, 2025 | msn.com

Trevena, Inc. (TRVN) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

Trevena Enters Securities Exchange Agreement with Investor

May 15, 2025 | tipranks.com

Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win

April 11, 2025 | readingeagle.comR

Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater

March 9, 2025 | msn.com

JMP Securities downgrades Trevena (TRVN) to a Hold

December 27, 2024 | markets.businessinsider.com

‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment

December 16, 2024 | yahoo.com

Lyme Regis town councillor John Trevena stand down

December 11, 2024 | bridportnews.co.ukB

Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

December 10, 2024 | zacks.com

Trevena appoints new financial chief

November 29, 2024 | investing.com

Trevena Appoints Katrine Sutton as New CFO

November 27, 2024 | tipranks.com

HC Wainwright & Co. Downgrades Trevena (TRVN)

November 16, 2024 | msn.com

Trevena, Inc. Navigates Financial Challenges and Strategic Changes

November 9, 2024 | msn.com

Chester County biopharm firm's latest layoffs impact its C-suite

November 7, 2024 | bizjournals.com

Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review

November 7, 2024 | fiercebiotech.comF

Trevena Reports Third Quarter 2024 Results and Provides Business Update

November 7, 2024 | globenewswire.com

Why Trevena (TRVN) Stock Is Down 43% Today

October 8, 2024 | msn.com

Trevena, Inc. Faces Delisting from Nasdaq

October 6, 2024 | msn.com

Trevena Announces Receipt of Nasdaq Delisting Notification

October 4, 2024 | globenewswire.com

Learn to Evaluate (TRVN) using the Charts

September 16, 2024 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVN, SONN, JAGX, and PCSA Company Descriptions

Jaguar Animal Health NASDAQ:JAGX

$2.10 -0.12 (-5.41%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$2.14 +0.04 (+2.14%)

As of 08/7/2025 07:45 PM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Heatwurx NASDAQ:PCSA

$0.23 +0.00 (+1.58%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$0.22 -0.01 (-4.80%)

As of 04:00 AM Eastern

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Sonnet BioTherapeutics NASDAQ:SONN

$2.88 -0.10 (-3.36%)

Closing price 08/7/2025 04:00 PM Eastern

Extended Trading

$2.90 +0.02 (+0.69%)

As of 08/7/2025 07:59 PM Eastern

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Trevena NASDAQ:TRVN

$0.25 0.00 (0.00%)

As of 08/6/2025

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time